Abstract: In this study, a quinoline derivate, clioquinol (5-chloro-7-iodoquinolin-8-ol), was evaluated against Leishmania amazonensis and Leishmania infantum promastigotes and amastigotes. The cytotoxicity in murine macrophages and human red blood cells, as well as the efficacy in treating infected macrophages and the inhibition of infection using pre-treated parasites were also evaluated. Results showed that clioquinol inhibited L. amazonensis and L. infantum promastigotes with effective concentration 50% (EC 50 ) values of 2.55 AE 0.25 and 1.44 AE 0.35 lg/mL, respectively, and of 1.88 AE 0.13 and 0.98 AE 0.17 lg/mL against axenic amastigotes, respectively. The cytotoxic EC 50 concentrations of clioquinol in murine macrophages and human red blood cells were, respectively, 255 AE 23 and 489 AE 20 lg/mL. With these results, the selectivity index was calculated, showing values of 99.9 and 177.1 against promastigotes, respectively, and of 135.6 and 260.1 against axenic amastigotes, respectively. Significant reductions in the percentage of infected macrophages after treatment using clioquinol were also observed, as well as when parasites were pre-treated with clioquinol and used to infect murine macrophages. The mechanism of action of clioquinol was investigated in L. amazonensis, and results revealed morphological and biochemical alterations in the clioquinol-treated parasites, including reduction in cell volume, loss of mitochondrial membrane potential, increase in the ROS production and rupture of the plasma membrane. The externalization of phosphatidylserine (PS) at the cell surface was evaluated in treated parasites that had been doubly labelled with annexin and propidium iodide (PI). The results showed no significant difference for PS exposure when compared to the untreated control, although a significant increase in the PI/annexin V-labelled cell population was found in the treated parasites. Results suggest that clioquinol induces a discontinuity of the parasite membrane, possibly related to a characteristic event of cell death caused by necrosis. This study demonstrates, for the first time, the antileishmanial activity of clioquinol against two relevant Leishmania species and suggests that the mitochondria of the parasites may be a possible biological target leading to parasite necrosis. Our findings suggest that clioquinol may have a potential application in treatment of leishmaniasis and further studies should be performed in infected mammalian hosts.
Leishmaniases are diseases able to cause high mortality and morbidity worldwide, with 380 million people at risk and 70,000 deaths being registered per year caused by the disease [1] . This disease complex is caused by the parasites of the genus Leishmania, with visceral leishmaniasis (VL) caused by the Leishmania donovani complex species, including L. donovani and L. infantum, and tegumentary leishmaniasis (TL) caused by L. braziliensis, L. guyanensis and L. amazonensis species in the Americas [2, 3] .
Drugs are an important tool to control the disease, and the treatment has been based on the administration of the pentavalent antimonials. However, these regimens are accompanied by several side effects, such as arrhythmias, renal and hepatic toxicity, among others [4] . In addition, parasite resistance to current drugs has increased [5] . Other compounds, such as amphotericin B (AmpB) and its liposomal formulations (pentamidine, paromomycin, miltefosine, among others), have also been employed for this purpose; however, side effects and/or high cost have been commonly reported [6, 7] .
Plants constitute an important source of new pharmaceuticals, and studies have been developed in an attempt to identify the bioactive molecules that could be employed for this purpose, such as quinoline, alkaloids, coumarins, tannins, saponins, cyclosporine, among others [8] [9] [10] [11] . As a consequence, an increasing awareness of the potential of these compounds might lead to the development of novel drugs for the treatment of neglected diseases, as the impact of natural products on drug discovery is considerable, not only for cancer, but also for parasitic infections [12, 13] .
Naphthoquinones are found in distinct plant families and are used in the traditional medicine for the treatment of diseases, particularly as anticancer agents [14, 15] . In addition, their derivatives present biological properties, such as antimicrobicidal and anticancer activities, which have stimulated the study of these bioactive compounds in the field of applied chemistry [16] . In this context, 8-hydroxyquinoline (8-HQN) has been characterized as a naphthoquinone-derived molecule presenting a variety of biological actions, such as protease inhibition, effect on cancer, Alzheimer's disease and Parkinson's disease, as well as antiparasitic and antibacterial effects [17] [18] [19] .
This molecule presented an antileishmanial activity against different Leishmania species [20] , and when it was incorporated to a Poloxamer 407-based delivery system, the compound proved to be effective in the treatment of L. amazonensis-or L. infantum-infected BALB/c mice [21, 22] . In this study, an 8-HQN derivate, clioquinol (5-chloro-7-iodoquinolin-8-ol), which presented antibacterial, antifungal and antiamebic activities [23, 24] , was tested against two Leishmania species able to cause VL and TL around the world. The antileishmanial activity against in vitro stationary promastigotes and intramacrophages amastigotes of L. amazonensis and L. infantum, seeking to obtain the effective concentration 50% (EC 50 ), as well as the 50% cytotoxic concentration (CC 50 ), in murine macrophages and in human red blood cells (RBC 50 ), was investigated. This study evaluated the efficacy of clioquinol in the treatment of infected macrophages, as well as the inhibition of infection using pre-treated parasites, and evaluated the mechanism of action of this molecule in L. amazonensis.
Materials and Methods
Ethics and mice. This study was approved by the Committee for the Ethical Handling of Research Animals (CEUA) of the Federal University of Minas Gerais (UFMG), logged under protocol number 085/2017 and was approved by the Human Research Ethics Committee (COEP/UFMG), logged under protocol number CAAE-32343114.9.0000.5149. BALB/c mice (female, 8 weeks old, weighing 20-25 g) were purchased from the UFMG Institute of Biological Sciences and were maintained within specific pathogen-free conditions. Peritoneal macrophages were obtained through peritoneal lavage using 5 mL of cold PBS 1x (phosphate-buffered saline: 137 mM NaCl, 8 mM Na 2 HPO 4 , 2.7 mM KCl, 1.5 mM KH 2 PO 4 , at pH 7.4). The peritoneal exudate cells were centrifuged at 1000 9 g for 10 min., and the pellet was resuspended in RPMI 1640 medium. Cells were then counted and plated into 96-well plates for the biological assays.
Parasites. Leishmania amazonensis (IFLA/BR/1967/PH-8) and L. infantum (MHOM/BR/1970/BH46) were used in this study. The parasites were grown in complete Schneider's medium (SigmaAldrich, St. Louis, MO, USA), which consisted of Schneider's medium plus 20% heat-inactivated foetal bovine serum (FBS, SigmaAldrich) and 20 mM L-glutamine pH 7.4 at 24°C. Stationary-phase promastigotes were cultured as described elsewhere [25] . To obtain the axenic amastigotes, a technical protocol was developed as described elsewhere, with few modifications [26] . Briefly, 1 9 10 9 stationary-phase promastigotes were washed three times in sterile phosphate buffer saline (PBS) 19 and incubated for 48 hr or 72 hr for L. amazonensis or L. infantum, respectively, in 5 mL FBS at 37°C. The parasites were then washed three times in PBS 1x, and their morphology was evaluated by staining performed with the Giemsa method.
Antileishmanial activity. The in vitro inhibition of Leishmania growth was evaluated by cultivating L. infantum or L. amazonensis stationary promastigotes and axenic amastigotes (1 9 10 6 cells) in the presence of clioquinol (0-20.0 lg/mL) (catalog number 130-26-7, SigmaAldrich) in 96-well culture plates (Nunc, Nunclon, Roskilde, Denmark) for 48 hr at 24°C. AmpB (0-1.0 lg/mL, Sigma-Aldrich) was used as a drug control. Cell viability was assessed using the colorimetric assay with 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyl tetrazolium bromide (MTT, Sigma-Aldrich) method. For this, MTT solutions were prepared at 5 mg/mL in PBS 1x, filtered and sterilized at the time of use, and 15 lL was added to each well. The optical density (O.D.) values were read in an ELISA microplate spectrophotometer (Molecular Devices, Spectra Max Plus, San Jose, CA, USA), at 570 nm. The effective concentration 50% (EC 50 ) of product was determined by applying a sigmoidal regression of a dose-response curve. The technical protocol was developed as described in Ref. [20] .
Cytotoxicity. Cytotoxicity was evaluated in murine macrophages and human red blood cells. The inhibition of 50% of the macrophage's viability (CC 50 ) was calculated by cultivating these cells (5 9 10 5 cells) with clioquinol (0-20.0 lg/mL) or AmpB (0-1.0 lg/mL) in 96-well plates (Nunc) for 48 hr at 37°C. Cell viability was evaluated by the MTT method, using the same concentrations of the reagent described above. The technical protocol was developed as described in Ref. [20] . The inhibitory concentration to 50% of human red blood cells (RBC 50 ) was evaluated as an additional cytotoxicity parameter. For this, an incubation with clioquinol (0-20.0 lg/mL) or AmpB (0-1.0 lg/mL) and a 5% red blood cell (human O type) suspension was performed for 1 hr at 37°C. Then, the suspension was centrifuged by 1000 9 g for 10 min., and the cell lyses percentage was determined spectrophotometrically at 570 nm. The absence (blank) or 100% of haemolysis were determined by replacing clioquinol for an equal volume of PBS 19 or distilled water, respectively, and the results were calculated by the haemolysis percentage as compared to the negative (PBS 1x) and positive (distilled water) controls, respectively.
Treatment of infected macrophages. Murine macrophages (5 9 10 5 cells) were seeded on round glass coverslips within 24-well plates in RPMI 1640 medium, which was supplemented with 20% FBS and 20 mM L-glutamine, pH 7.4, and incubated for 24 hr at 37°C in 5% CO 2 . Stationary promastigotes (5 9 10 6 cells, in a ratio of 10 parasites per one macrophage) were then added to the wells, and cultures were incubated for 48 hr at 37°C in 5% CO 2 . Free parasites were removed by extensive washing with RPMI 1640 medium, while infected macrophages were treated with clioquinol (5.0, 10.0, and 15.0 lg/mL) or AmpB (0.1, 0.5, and 1.0 lg/mL) for 48 hr at 24°C in 5% CO 2 . After fixation with 4% paraformaldehyde, treated and infected macrophages were stained by Giemsa, and the percentage of infected cells, as well as the number of intramacrophage amastigotes of 200 cells, were determined in an optical microscope.
Inhibition of infection using pre-treated parasites. To evaluate the inhibition of infection using pre-treated parasites, stationary promastigotes (5 9 10 6 cells) were first incubated with clioquinol (5.0, 10.0 and 15.0 lg/mL) or AmpB (0.1, 0.5 and 1.0 lg/mL) for 1 hr at 24°C. After, treated parasites were washed three times in RPMI 1640 medium, quantified and incubated with murine macrophages (at a ratio of 10 parasites per one macrophage) for 24 hr at 37°C in 5% CO 2 . These were then washed and stained by Giemsa to evaluate both the percentage of infected macrophages as well as the number of intramacrophage amastigotes of 200 cells in an optical microscope.
Morphology and cell volume in clioquinol-treated L. amazonensis. To evaluate the cell volume and morphology, promastigotes (1 9 10 cells) were untreated (control) or treated with 2.55 and 5.10 lg/mL of clioquinol (corresponding to 1 and 2 times the EC 50 value, respectively) for 6 hr at 25°C. Thereafter, parasites were harvested and fixed in 4% paraformaldehyde for 20 min., washed with PBS 1x, placed on glass slides and stained with Giemsa. Slides were analysed by optical microscopy (Olympus BX53, Shinjuku, Tokyo, Japan) and photographed (Olympus DP73), using a 1009 objective lens. To assess the cell volume, treated or untreated parasites were analysed on a FACsCANTO II flow cytometer equipped with DIVA software (Joseph Trotter, Scripps Research Institute, La Jolla, CA, USA). A total of 10,000 events were acquired, analysing the FSC (forward scatter) parameter, which was correlated with the cell volume. Three independent experiments were carried out in duplicate.
Mitochondrial membrane potential in clioquinol-treated parasites. Studies for the evaluation of DΨm were performed using the Mitotracker â Red CM-H2XROS (MTk) and rhodamine 123 (Rh123) probes. For this, promastigotes (1 9 10 7 cells) were also treated with clioquinol (2.55 and 5.10 lg/mL) for 6 hr at 25°C. The cells were then harvested, washed and incubated with MTk (500 nM) or Rh123 (0.5 lg/mL) for 40 or 15 min., respectively. Cells stained with MTk were washed, resuspended in PBS 19 and transferred to 96-well clear bottom black microplates, at which time the fluorescence intensity was evaluated by a spectrofluorometer (FLx800), with an excitation wavelength of 540 nm and an emission of 600 nm. A potent mitochondrial oxidative phosphorylation uncoupler (FCCP; 5.08 lg/ mL) was used as a positive control. Rh123-labelled parasites were analysed by a FACsCanto II flow cytometer equipped with DIVA software, and a total of 10,000 events were acquired in each sample using the FITC channel. The variation index (VI) of the fluorescence intensity of Rh123 was determined by the equation (MT-MC)/MC, in which MT is the mean of the treated parasites and MC is the mean of untreated parasites. Negative VI values indicated depolarization of parasite mitochondrial membrane potential. Miltefosine (18.0 lg/mL) was used as a control.
Reactive oxygen species in clioquinol-treated L. amazonensis. The ROS production in L. amazonensis promastigotes was evaluated in the treated parasites, as described in [27] . Briefly, promastigotes (1 9 10 7 cells) were incubated alone or with clioquinol (2.55 and 5.10 lg/mL) for 6 hr at 25°C. Parasites were incubated with a 2-,7-dichlorodihydrofluorescein diacetate (H 2 DCFDA) fluorescent probe, for 30 min. in the dark at room temperature. The ROS production was evaluated fluorometrically with an excitation wavelength of 485 nm and an emission of 528 nm. Miltefosine (18.0 lg/mL) was used as a control.
Plasma membrane integrity and phosphatidylserine (PS) exposure in clioquinol-treated parasites. To evaluate the apoptosis-/necrosisrelated mechanisms in clioquinol-treated L. amazonensis, promastigotes (1 9 10 7 cells) were untreated or treated with clioquinol (2.55 and 5.10 lg/mL) for 6 hr at 25°C. After, they were washed in PBS 19 and incubated with 1.0 mg/mL of propidium iodide (PI), during 15 min. at room temperature. The plasma membrane integrity was evaluated by fluorescence intensity as described in [28] . Promastigotes warmed at 65°C were used as a positive control. To evaluate PS exposure, treated parasites were incubated with annexin V-FITC (Invitrogen, USA) for 15 min. at room temperature, at which time they were incubated with PI (1.0 lg/ mL) for 15 min., and reactions were evaluated by flow cytometry. A total of 10,000 events were acquired using the FITC and PE channels, and miltefosine (18.0 lg/mL) was used as a control.
Analysis of cell cycle in clioquinol-treated parasites. The analysis of cell cycle was performed as described in [29] . Briefly, L. amazonensis promastigotes (1 9 10 7 cells) were untreated or treated with clioquinol (2.55 and 5.10 lg/mL) for 6 hr at 25°C. After having been washed, parasites were permeabilized, incubated with ribonuclease (200.0 lg/mL) for 1 hr at 37°C and labelled with PI (7.0 lg/mL) for 20 min. Data acquisition and analysis were performed using a CytoFLEX flow cytometer (Beckman Coulter, Indianapolis, IN, USA) equipped with CytExpert 2.0 software (Beckman Coulter). A total of 5000 events were acquired using a PI610ND-A channel. Experiments were performed in three replicates, each one in duplicate.
In vivo toxic effects. BALB/c mice (n = 8 per group) were subcutaneously inoculated, once a day, in their left hind footpad with PBS 1x, AmpB (1.0 mg/kg of body-weight) or clioquinol (50.0 mg/kg of body-weight) for 10 days. Variations in body-weight and clinical signs were monitored daily. One day after the end of treatment, blood samples were collected for biochemical analysis, when the cardiac function was analysed by the dosage of creatine kinase-MB, while the hepatic function was analysed by quantifying aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Nephrotoxicity was evaluated by examining the levels of blood urea nitrogen (BUN) and serum creatinine (CRTN). Experiments were performed using commercial kits (Labtest Diagnostica â , Belo Horizonte, Minas Gerais, Brazil), each of which was repeated twice.
Statistical analysis. The results were evaluated using Microsoft Excel (version 10.0) and analysed using GraphPad Prism TM (version 6.0 for Windows). The EC 50 and CC 50 values were calculated from the mean percentage reduction of the stationary promastigotes (EC 50 ) or murine macrophages (CC 50 ), respectively, when compared to that in the untreated controls. The curves were determined by applying sigmoidal regression to the logarithm concentration/response data. The one-way analysis of variance (ANOVA), followed by Dunnett's test or the Bonferroni post-test, was used to compare the groups. Differences were considered significant when p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) and p < 0.0001 (****).
Results
Antileishmanial activity and cytotoxicity induced by clioquinol. The in vitro antileishmanial activity of clioquinol was investigated against two Leishmania species, and AmpB was used as a control. Results showed EC 50 values of 2.55 AE 0.25 and 1.44 AE 0.35 lg/mL for clioquinol against L. amazonensis and L. infantum promastigotes, respectively, while these values were of 0.10 AE 0.02 and 0.07 AE 0.03 lg/mL, respectively, when using AmpB. The EC 50 values against L. amazonensis and L. infantum axenic amastigotes were of 1.88 AE 0.13 and 0.98 AE 0.17 lg/mL for clioquinol, respectively. Using AmpB, the values were of 0.14 AE 0.03 and 0.05 AE 0.02 lg/mL, respectively (table 1) . Regarding cytotoxicity, the CC 50 values were of 254.90 AE 22.60 and 1.00 AE 0.13 lg/mL for clioquinol and AmpB, respectively. With these data, the selectivity index (SI) was calculated by the ratio between CC 50 and EC 50 values, and results were of 99.9 and 177.1 for clioquinol against L. amazonensis and L. infantum promastigotes, respectively, and of 135.6 and 260.1 against axenic amastigotes, respectively (table 2) . For AmpB, these values were of 10.0 and 14.3 against L. amazonensis and L. infantum promastigotes, respectively, and of 7.1 and 20.0 against axenic amastigotes, respectively. Like an additional parameter of cytotoxicity, the haemolytic activity was also evaluated, and results were of 488.90 AE 19.5 and 13.50 AE 2.20 lg/mL for clioquinol and AmpB, respectively (table 2).
Treatment of infected macrophages.
The effect of the clioquinol in treating infected macrophages was evaluated. In the results using L. infantum, the infection percentage in treated and infected cells and the number of recovered amastigotes were of 10.5% AE 1.7% and 0.2 AE 0, respectively, when 15.0 lg/mL of clioquinol was used in the experiments. Using L. amazonensis, these values were of 6.6% AE 0.8% and 0.1 AE 0, respectively (table 3). The infectiveness reduction was calculated, and results in L. infantum showed a drop in infection in the order of 85.5% when infected macrophages were treated with 15.0 lg/mL of clioquinol, and of 92.7% when L. amazonensis-infected macrophages were treated with this molecule in the same concentration. Using AmpB, infection percentage in treated and infected cells and the number of recovered amastigotes were of 10.3% AE 1.8% and 0.2 AE 0, respectively, when 1.0 lg/mL of this molecule was employed. Using L. amazonensis, these values were of 11.2% AE 2.2% and 0.4 AE 0.1, respectively. The infectiveness reduction was also calculated and showed a drop in infection in the order of 85.8% in treated and L. infantum-infected cells, and of 87.5% when L. amazonensis-infected macrophages were treated with AmpB. When macrophages were infected and untreated, infection percentage was of 72.3% AE 4.1% and 89.9% AE 4.5%, respectively, using L. infantum and L. amazonensis, while the number of recovered amastigotes was of 3.9 AE 0.2 and 7.7 AE 0.5, respectively.
Inhibition of infection using pre-treated parasites. An analysis to evaluate the inhibitory potential of clioquinol in Leishmania was performed by incubating this molecule with parasite promastigotes, which were later used to infect murine macrophages. In the results, when L. infantum was incubated with clioquinol (15.0 lg/mL), the infection percentage and the number of recovered amastigotes were of 16.5% AE 3.5% and 0.3 AE 0.1, respectively, whereas against L. amazonensis, these values were of 19.8% AE 1.9% and 0.3 AE 0.1, respectively (table 4). Using AmpB (1.0 lg/mL), the infection percentage was of 18.7% AE 2.4% and 22.3% AE 3.2% for L. infantum and L. amazonensis, respectively, and the number of recovered amastigotes was of 0.5 AE 0.2 and 0.6 AE 0.1, respectively. When parasites were untreated and used to infect macrophages, the infection percentage was of 79.8% AE 3.3% and 93.4% AE 5.5% for L. infantum and L. amazonensis, respectively, and the number of recovered amastigotes was of 4.4 AE 0.5 and 8.6 AE 0.8, respectively. The promastigotes and axenic amastigotes of the parasites (1 9 10 6 cells) were incubated with clioquinol (0-20.0 lg/mL) for 48 hr at 24°C, at which time the cell viability was analysed by MTT assay. Amphotericin B (0-1.0 lg/mL) was used as a control. In addition, murine macrophages (5 9 10 5 ) were also incubated with the compounds, and the cytotoxicity was evaluated by the MTT method. The results were expressed as mean AE standard deviation of the groups. 1 Inhibition of 50% of the Leishmania viability (EC 50 ). 2 Inhibitory concentration to 50% of murine macrophages (CC 50 ). The data shown represent the mean AE standard deviation of three independent experiments. The inhibitory concentration to 50% of human red blood cells (RBC 50 ) 1 was evaluated as cytotoxicity parameter For this, an incubation with clioquinol (0-20.0 lg/mL) or AmpB (0-1.0 lg/mL) and a 5% red blood cell (human O type) suspension was performed for 1 hr at 37°C. Then, the suspension was centrifuged by 1000 9 g for 10 min., and the cell lyses percentage was determined spectrophotometrically at 570 nm. The data shown represent the mean AE standard deviation of three independent experiments.
Mechanism of action in L. amazonensis. This study used an optical microscopy and flow cytometry assay, aimed at evaluating whether or not treatment with clioquinol causes morphological alterations in L. amazonensis promastigotes. In the results, the treatment using clioquinol induced changes in the cell motility and morphological appearance. Photomicrography, when compared to untreated parasites, showed rounded promastigotes, enveloped flagellum and a subtle decrease in cell volume ( fig. 1 ). In addition, flow cytometry assays confirmed a significant reduction in cell volume after the treatment with clioquinol ( fig. 2) . Alterations in the mitochondrial membrane potential (DΨm) of the parasites were then evaluated. The results showed that treatment, when compared to negative control, induced a significant reduction in the MTk fluorescence intensity in the order of 14.99% and 16.09%, respectively ( fig. 3 ). In addition, clioquinol-treated promastigotes and those labelled with the Rh123 fluorescent probe, showed a significant reduction in their fluorescence intensity in relation to untreated parasites. These results suggested that treatment using clioquinol induces DΨm alterations in promastigote forms. The fluorescent probe H2DCFDA was used to evaluate the ROS production in clioquinol-treated parasites, and the subsequent results revealed significant increases in the fluorescence intensity in the order of 3.99 and 4.06 times, respectively, when compared to the untreated controls ( fig. 4) , suggesting that the treatment with clioquinol induced oxidative stress in L. amazonensis.
Evaluating the plasma membrane integrity, clioquinol-treated promastigotes were labelled with PI and evaluated. Results, when compared to untreated controls, showed a significant increase in their fluorescence intensity ( fig. 5 ). These data indicated that an internalization of the fluorescent marker had occurred, suggesting that the treatment with clioquinol caused the rupture of the parasite membrane. As the loss of plasma membrane is one indicator of death by apoptosis, we analysed if the treatment could induce the externalization of PS at the cell surface. For this, promastigotes were treated and doubly labelled with annexin and PI and were then evaluated by flow cytometry. Results showed no significant difference for PS exposure (lower right quadrant) when compared to the untreated control. However, a significant population of PI-labelled cells (upper left quadrant) was directly proportional to the concentration of clioquinol used in the treatment, when compared to the untreated control ( fig. 6 ). In addition, the treatment induced a significant increase in the PI/annexin V-labelled cell population (right upper quadrant). These results suggested that clioquinol induces a discontinuity of the parasite membrane, possibly related to a characteristic event of cell death caused by necrosis. We have investigated if the treatment with clioquinol could induce changes in the cell cycle. The results showed that clioquinol did not interfere in the cell cycle, and an increase in cells in the sub-G 0 /G 1 peak (DNA fragmentation), characteristic of cells in apoptosis, was not observed (fig. 7) . By contrast, miltefosine presented a significant increase in the sub-G 0 /G 1 population (52.77%), when compared to untreated controls.
Toxicity in a mammalian model. As the core purpose of this study is to develop a product to be used against leishmaniasis in infected mammalian hosts, ) were previously infected with L. amazonensis or L. infantum stationary promastigotes (in a ratio of 10 parasites per one macrophage), and later treated with clioquinol (5.0, 10.0 and 15.0 lg/mL) for 48 hr at 24°C in 5% CO 2 . Amphotericin B (0.1, 0.5, and 1.0 lg/mL) was used as a drug control. The percentage of infected macrophages, the number of recovered amastigotes and the infection reduction in treated macrophages were calculated by applying a sigmoidal regression of concentration-inhibition curves determined by counting 200 cells per coverslip, in triplicate. The data shown represent the mean AE standard deviation of three independent experiments. the in vivo side effects induced by clioquinol in BALB/c mice have been analysed through clinical and biochemical evaluations in the animals that received the treatment for 10 days. As a control, mice received saline or AmpB. The levels of the cardiac, hepatic and renal markers were measured, which demonstrated that clioquinol-treated mice presented unchanged amounts of these enzymes, while AmpB-treated animals presented higher levels of AST, ALT, BUN and CRTN, reflecting hepatic and renal toxicity. In addition, loss of weight and weakness were signals observed in AmpB-treated mice, which also showed a negative variation in the order of 6% in their body-weight. By contrast, clioquinol-treated animals showed no clinical alteration, as well as a positive body-weight variation of 5% was observed at the end of the experiment.
Discussion
The antileishmanial drugs currently available to treat against leishmaniases present limitations due to the high cost of the liposomal AmpB formulations; the systemic toxicity of the old therapeutics, as well as the difficult to administer them; and the increase in parasite resistance. In this context, there is an urgent need to discover new, safe and more effective products to be applied against this disease [30] . In this light, plants are The inhibitory effect of clioquinol on the Leishmania infection in murine macrophages was evaluated using pre-treated L. amazonensis or L. infantum promastigotes to infect these cells. For this, parasites (5 9 10 6 ) were first incubated with clioquinol (5.0, 10.0 and 15.0 lg/mL) or AmpB (0, 0.1, 0.5 and 1.0 lg/mL) for 1 hr at 24°C. Cells were then washed three times in an RPMI 1640 medium, quantified and incubated with macrophages (5 9 10 5 cells) for 24 hr at 37°C in 5% CO 2 . After, cells were washed and stained by Giemsa method to evaluate the percentage of infected macrophages, the number of intramacrophage amastigotes and the reduction of macrophage infection, which were determined by counting 200 cells in triplicate. The data shown represent the mean AE standard deviation of three independent experiments. A B C Fig. 1 . Clioquinol causes changes in the morphology of Leishmania promastigotes. To verify whether the compound clioquinol causes changes in the Leishmania amazonensis morphology, promastigotes (1 9 10 7 cells) were untreated (A) or treated with 2.55 lg/mL (B) or 5.10 lg/mL (C) of the compound, then fixed in 4% paraformaldehyde, placed on glass slides and stained with Giemsa. Slides were analysed by optical microscopy and photographed at 100 times magnification. The arrows show promastigotes with rolled flagella and altered cell morphology. Images are representative of three independent experiments performed in triplicate.
considered to be an authentic source to identify new and effective biological compounds, which should be exploited for the development of new antileishmanial compounds [31] . It has been estimated that there are about 250,000 medicinal plant species in the world. Nevertheless, the biological activity of only 6% of them has been studied, and about 1% of medicinal compounds have been developed and are being tested in clinical trials [7, 32] .
The pharmacological properties of the quinoline ring illustrate the number of commercial products containing this heterocyclic system [33] . Quinoline-based compounds present a variety of biological actions, such as antimalarial and antileishmanial agents [28, 34, 35] . As a consequence, this study illustrates the leishmanicidal activity of 8-HQN, a quinoline derivate, against distinct Leishmania species [20] . Thus, as part of a wider survey on this class of molecules, the present study investigated the antileishmanial activity of clioquinol, a quinoline derivative, against stationary promastigotes and intracellular amastigotes of L. amazonensis and L. infantum, as well as evaluated the mechanism of action and the in vivo effects of this molecule when administered in naive BALB/c mice.
In this study, clioquinol exhibited a strong and selective antileishmanial activity against in vitro and in vivo L. infantum and L. amazonensis promastigotes and amastigotes. This effect was accompanied by a low toxicity against murine macrophages Fig. 2 . Clioquinol alters the cell volume of Leishmania amazonensis promastigotes. To verify whether the clioquinol alters the cell volume, promastigotes (1 9 10 7 cells) were treated with clioquinol (2.55 or 5.10 lg/mL). After, they were washed with PBS 19 and evaluated by flow cytometry aiming to observe the FSC parameter (Forward Scatter). The evaluation was interpreted using the FCS Express V3 software, and the statistical differences were indicated by Dunnett's test: (***) p < 0.001 and (****) p < 0.0001. ICHQ, clioquinol. and human red blood cells, with no toxic effects observed in any of the tested concentrations of this molecule. In addition, the selectivity index of clioquinol was much higher than AmpB, a known drug used to treat leishmaniasis; consequently, additional assays were performed to elucidate the mechanism of action of clioquinol related to parasite death.
Several studies have shown that mitochondria are important targets in the mechanism of death in Trypanosomatids. As this organelle is unique in these protozoa, the collapse of the mitochondrial membrane potential is known as one characteristic metabolic process of cell death in these parasites [28, [36] [37] [38] . There are multiple sources of ROS to the cells [9, 39] , and the mitochondrial collapse associated with cell membrane depolarization has been related to apoptosis and/or necrosis events [40] . Here, treatment with clioquinol induced a significant increase in the production of ROS in all of the tested concentrations. In fact, the DΨm of the parasites was measured, and the results showed that treatment with clioquinol reduced the parasite's DΨm, when compared to untreated controls. Others have also associated the action of quinoline derivatives with the Leishmania mitochondria dysfunction [41, 42] .
In this context, the mechanism of cell death triggered by clioquinol was also evaluated as regards their effect on the plasma membrane of the parasites. The results showed that the treatment with this compound altered the integrity of the plasma membrane in Leishmania. Our data showed that clioquinol induced a significant permeabilization of the parasite membrane, when compared to the untreated cells, thus demonstrating that the parasites most likely undergo cell death by necrosis. Although clioquinol-treated promastigotes induced the depolarization of DΨm and cell shrinkage (both feature characteristics that are suggestive of apoptosis), neither PS exposure on the external leaflet of the plasma membrane nor G 0 /G 1 phase cell cycle arrest was found. In this context, it can be concluded that the mechanism of death induced by clioquinol was compatible with necrosis.
As the purpose of this study was to identify new therapeutics to be used in the in vivo treatment against leishmaniasis, a toxicity study was performed in BALB/c mice, which received high daily doses of clioquinol for 10 days. AmpB was used as a control. One day after the end of treatment, high levels of renal and hepatic enzymes were found in the AmpB-treated mice, as compared to those that had received clioquinol, indicating an organic toxicity in the animals caused by AmpB. Others have also found hepato and nephrotoxicity caused by AmpB in murine models treated against leishmaniasis [43] [44] [45] [46] . As a consequence, we can infer that the administration of clioquinol in these mammalian hosts can be considered safe, as no toxicity was observed in the animals, thus suggesting a wide safety margin in therapeutic doses of this compound, as well as opening the possibility to use this molecule in future studies for the treatment of Leishmania-infected hosts. cells) were untreated or treated with clioquinol (2.55 and 5.10 lg/mL) and incubated for 6 hr. Subsequently, cells were incubated with propidium iodide, and the fluorescence intensity was determined by spectrofluorometer. Heated (65°C) promastigotes were used as a positive control. Bars indicate the mean plus standard deviation of the groups, which were calculated with results obtained in three independent experiments. The statistical differences were indicated by Dunnett's test: (*) p < 0.05, (***) p < 0.001, and (****) p < 0.0001. ICHQ, clioquinol.
In summary, the data from the present study showed that clioquinol presents a selective antileishmanial activity against two important Leishmania species in the world, as well as a rapid in vitro effect, manifesting changes in membrane permeability, mitochondrial functionality and parasite morphology. In addition, the ability of clioquinol to reduce Leishmania infection in murine macrophages, as well as its effectiveness in inhibiting the infection of these cells using pre-treated parasites, demonstrates that clioquinol should be tested in future studies to treat mammalian models against Leishmania spp. infection, as well as to inhibit parasite infection. Fig. 6 . Clioquinol not induces phosphatidylserine exposure in Leishmania amazonensis. Promastigotes (1 9 10 7 cells) were incubated with clioquinol (2.55 and 5.10 lg/mL) for 6 hr and doubly labelled with annexin V-FITC and PI. Analyses were performed by flow cytometry. A total of 10,000 events were acquired using the FITC and PE channels. Miltefosine (18.0 lg/mL) was used as a positive control. The upper left quadrants show a percentage of PI-labelled cells, while the lower shows unmarked cells. The lower right quadrants show annexin V-labelled cells, while the upper right quadrants show double-labelled cells with PI and annexin V. The dot plots presented are representative of three independent experiments. Statistical differences were performed on GraphPad Prism 6.0 software by analysis of variance (One-Way ANOVA), and differences were analysed by Dunnett's test: (*) p < 0.05, (***) p < 0.001, and (****) p < 0.0001. ICHQ, clioquinol. Fig. 7 . Clioquinol does not interfere in the Leishmania amazonensis cell cycle. Promastigotes (1 9 10 7 cells) were untreated (negative control) or treated with clioquinol (2.55 and 5.10 lg/mL) for 6 hr, permeabilized with 70% ethanol, incubated with ribonuclease and labelled with PI. DNA content was analysed by flow cytometry, and a total of 5000 events were acquired using a PI610ND-A channel. Graph form (A) and percentage of cells (B) present in each phase of the cell cycle are shown. Bars indicate the mean plus standard deviation of the groups, which were calculated with results obtained in three independent experiments. The statistical differences were indicated by the Bonferroni post-test: (****) p < 0.0001. ICHQ, clioquinol.
